Glypican-3 expression in malignant small round cell tumors

Yuichi Shibui, Kina Miyoshi, Kenichi Kohashi, Yoshiaki Kinoshita, Masaaki Kuda, Hidetaka Yamamoto, Tomoaki Taguchi, Yoshinao Oda

Research output: Contribution to journalArticle

Abstract

Malignant small round cell tumors usually progress rapidly and show resistance to chemotherapy, and it is often difficult to make a definitive diagnosis based on their histological morphology. Glypican-3 (GPC3) is a highly tumor-specific antigen, and the overexpression of GPC3 was reported in many pediatric and adult malignancies. In the present study, we investigated the GPC3 expression in pediatric malignant small round cell tumors to assess its role in the differential diagnosis of the tumors. Immunohistochemistry was performed to assess the expression of GPC3 in samples from 84 rhabdomyosarcomas (RMSs; 44 alveolar and 40 embryonal RMSs), 62 Ewing sarcomas (EWSs), 35 neuroblastomas (NBs) and two desmoplastic small round cell tumors (DSRCTs). We performed a reverse transcription-quantitative polymerase chain reaction for GPC3 to determine the GPC3 mRNA expression in samples from 66 frozen tumors (23 RMSs, 28 EWSs and 15 NBs). The serum expression levels of GPC3 were analyzed in pre-operative blood samples from two RMS and eight NB patients. In total, 25% (21/84) of the RMSs and 3% (1/35) of the NBs exhibited a focal expression of GPC3, whereas, the other specimens showed no GPC3 expression. The GPC3 mRNA expression level of the RMSs with positive GPC3 expression (n=6) was significantly higher compared with the RMSs without such expression (n=17). A total of two cases of NB showed high serum levels of GPC3, but neither tumor showed immunoreactivity for GPC3. The immunohistochemical overexpression of GPC3 may be a candidate ancillary parameter in the differential diagnosis of RMS from EWS and DSRCT.

Original languageEnglish
Pages (from-to)3523-3528
Number of pages6
JournalOncology Letters
Volume17
Issue number3
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Glypicans
Neoplasms
Neuroblastoma
Ewing's Sarcoma
Desmoplastic Small Round Cell Tumor
Differential Diagnosis
Pediatrics
Messenger RNA
Rhabdomyosarcoma
Neoplasm Antigens

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Glypican-3 expression in malignant small round cell tumors. / Shibui, Yuichi; Miyoshi, Kina; Kohashi, Kenichi; Kinoshita, Yoshiaki; Kuda, Masaaki; Yamamoto, Hidetaka; Taguchi, Tomoaki; Oda, Yoshinao.

In: Oncology Letters, Vol. 17, No. 3, 01.03.2019, p. 3523-3528.

Research output: Contribution to journalArticle

Shibui, Yuichi ; Miyoshi, Kina ; Kohashi, Kenichi ; Kinoshita, Yoshiaki ; Kuda, Masaaki ; Yamamoto, Hidetaka ; Taguchi, Tomoaki ; Oda, Yoshinao. / Glypican-3 expression in malignant small round cell tumors. In: Oncology Letters. 2019 ; Vol. 17, No. 3. pp. 3523-3528.
@article{7a173abd0c4348359329961066101b0a,
title = "Glypican-3 expression in malignant small round cell tumors",
abstract = "Malignant small round cell tumors usually progress rapidly and show resistance to chemotherapy, and it is often difficult to make a definitive diagnosis based on their histological morphology. Glypican-3 (GPC3) is a highly tumor-specific antigen, and the overexpression of GPC3 was reported in many pediatric and adult malignancies. In the present study, we investigated the GPC3 expression in pediatric malignant small round cell tumors to assess its role in the differential diagnosis of the tumors. Immunohistochemistry was performed to assess the expression of GPC3 in samples from 84 rhabdomyosarcomas (RMSs; 44 alveolar and 40 embryonal RMSs), 62 Ewing sarcomas (EWSs), 35 neuroblastomas (NBs) and two desmoplastic small round cell tumors (DSRCTs). We performed a reverse transcription-quantitative polymerase chain reaction for GPC3 to determine the GPC3 mRNA expression in samples from 66 frozen tumors (23 RMSs, 28 EWSs and 15 NBs). The serum expression levels of GPC3 were analyzed in pre-operative blood samples from two RMS and eight NB patients. In total, 25{\%} (21/84) of the RMSs and 3{\%} (1/35) of the NBs exhibited a focal expression of GPC3, whereas, the other specimens showed no GPC3 expression. The GPC3 mRNA expression level of the RMSs with positive GPC3 expression (n=6) was significantly higher compared with the RMSs without such expression (n=17). A total of two cases of NB showed high serum levels of GPC3, but neither tumor showed immunoreactivity for GPC3. The immunohistochemical overexpression of GPC3 may be a candidate ancillary parameter in the differential diagnosis of RMS from EWS and DSRCT.",
author = "Yuichi Shibui and Kina Miyoshi and Kenichi Kohashi and Yoshiaki Kinoshita and Masaaki Kuda and Hidetaka Yamamoto and Tomoaki Taguchi and Yoshinao Oda",
year = "2019",
month = "3",
day = "1",
doi = "10.3892/ol.2019.9976",
language = "English",
volume = "17",
pages = "3523--3528",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Glypican-3 expression in malignant small round cell tumors

AU - Shibui, Yuichi

AU - Miyoshi, Kina

AU - Kohashi, Kenichi

AU - Kinoshita, Yoshiaki

AU - Kuda, Masaaki

AU - Yamamoto, Hidetaka

AU - Taguchi, Tomoaki

AU - Oda, Yoshinao

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Malignant small round cell tumors usually progress rapidly and show resistance to chemotherapy, and it is often difficult to make a definitive diagnosis based on their histological morphology. Glypican-3 (GPC3) is a highly tumor-specific antigen, and the overexpression of GPC3 was reported in many pediatric and adult malignancies. In the present study, we investigated the GPC3 expression in pediatric malignant small round cell tumors to assess its role in the differential diagnosis of the tumors. Immunohistochemistry was performed to assess the expression of GPC3 in samples from 84 rhabdomyosarcomas (RMSs; 44 alveolar and 40 embryonal RMSs), 62 Ewing sarcomas (EWSs), 35 neuroblastomas (NBs) and two desmoplastic small round cell tumors (DSRCTs). We performed a reverse transcription-quantitative polymerase chain reaction for GPC3 to determine the GPC3 mRNA expression in samples from 66 frozen tumors (23 RMSs, 28 EWSs and 15 NBs). The serum expression levels of GPC3 were analyzed in pre-operative blood samples from two RMS and eight NB patients. In total, 25% (21/84) of the RMSs and 3% (1/35) of the NBs exhibited a focal expression of GPC3, whereas, the other specimens showed no GPC3 expression. The GPC3 mRNA expression level of the RMSs with positive GPC3 expression (n=6) was significantly higher compared with the RMSs without such expression (n=17). A total of two cases of NB showed high serum levels of GPC3, but neither tumor showed immunoreactivity for GPC3. The immunohistochemical overexpression of GPC3 may be a candidate ancillary parameter in the differential diagnosis of RMS from EWS and DSRCT.

AB - Malignant small round cell tumors usually progress rapidly and show resistance to chemotherapy, and it is often difficult to make a definitive diagnosis based on their histological morphology. Glypican-3 (GPC3) is a highly tumor-specific antigen, and the overexpression of GPC3 was reported in many pediatric and adult malignancies. In the present study, we investigated the GPC3 expression in pediatric malignant small round cell tumors to assess its role in the differential diagnosis of the tumors. Immunohistochemistry was performed to assess the expression of GPC3 in samples from 84 rhabdomyosarcomas (RMSs; 44 alveolar and 40 embryonal RMSs), 62 Ewing sarcomas (EWSs), 35 neuroblastomas (NBs) and two desmoplastic small round cell tumors (DSRCTs). We performed a reverse transcription-quantitative polymerase chain reaction for GPC3 to determine the GPC3 mRNA expression in samples from 66 frozen tumors (23 RMSs, 28 EWSs and 15 NBs). The serum expression levels of GPC3 were analyzed in pre-operative blood samples from two RMS and eight NB patients. In total, 25% (21/84) of the RMSs and 3% (1/35) of the NBs exhibited a focal expression of GPC3, whereas, the other specimens showed no GPC3 expression. The GPC3 mRNA expression level of the RMSs with positive GPC3 expression (n=6) was significantly higher compared with the RMSs without such expression (n=17). A total of two cases of NB showed high serum levels of GPC3, but neither tumor showed immunoreactivity for GPC3. The immunohistochemical overexpression of GPC3 may be a candidate ancillary parameter in the differential diagnosis of RMS from EWS and DSRCT.

UR - http://www.scopus.com/inward/record.url?scp=85062059839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062059839&partnerID=8YFLogxK

U2 - 10.3892/ol.2019.9976

DO - 10.3892/ol.2019.9976

M3 - Article

AN - SCOPUS:85062059839

VL - 17

SP - 3523

EP - 3528

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 3

ER -